RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Total non-current liabilities

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$82.2B
P/E ratio
SummaryFinancials
Period EndTotal non-current liabilities (Million USD)YoY (%)
Dec 31, 20244,462+21.11%
Dec 31, 20233,684+8.05%
Dec 31, 20223,409+24.72%
Dec 31, 20212,734-20.55%
Dec 31, 20203,441+112.53%
Dec 31, 20191,619+5.51%
Dec 31, 20181,534+3.35%
Dec 31, 20171,485+15.75%
Dec 31, 20161,283+12.21%
Dec 31, 20151,143+69.39%
Dec 31, 2014675-3.61%
Dec 31, 2013700+4.25%
Dec 31, 2012672-2.61%
Dec 31, 2011690+52.37%
Dec 31, 2010453

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)